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Leprosy is a neglected tropical disease and an important public health problem, especially in developing 
countries. It is a chronic infectious disease that is caused by Mycobacterium leprae, which has a predilection 
for the skin and peripheral nerves. Although it has low sensitivity, slit-skin smear (SSS) remains the 
conventional auxiliary laboratory technique for the clinical diagnosis of leprosy. Polymerase chain reaction 
(PCR) is a molecular biology technique that holds promise as a simple and sensitive diagnostic tool. In 
the present study, the performance of two PCR methods, using different targets, PCR-LP and PCR-P, were 
compared with SSS with regard to leprosy diagnosis in a reference laboratory. M. leprae DNA was extracted 
from 106 lymph samples of 40 patients who had clinical suspicion of leprosy. The samples were subjected 
to both PCR techniques and SSS. Amplification of the human b-globin gene was used as PCR inhibitor 
control. The specificity of both PCR techniques was 100%, and sensitivity was 0.007 and 0.015 µg/ml 
for PCR-LP and PCR-P, respectively. No significant difference was found between either the PCR-LP or 
PCR-P results and SSS results (p > 0.05). Although PCR is not yet a replacement for SSS in the diagnosis 
of leprosy, this technique may be used as an efficient auxiliary tool for early detection of the disease, 
especially in endemic regions. This strategy may also be useful in cases in which SSS results are negative 
(e.g., in paucibacillary patients) and cases in which skin biopsy cannot be performed.
Uniterms: Leprosy/clinical diagnosis. Polymerase chain reaction/clinical diagnosis use. Mycobacterium 
leprae. 
A hanseníase é uma doença tropical negligenciada e ainda um importante problema de saúde pública, 
especialmente nos países em desenvolvimento. É uma doença infecciosa crônica causada pelo 
Mycobacterium leprae, que tem predileção pela pele e nervos periféricos. Embora com baixa sensibilidade, 
o esfregaço de linfa (SSS) continua sendo o método laboratorial convencional auxiliar no diagnóstico 
clínico da hanseníase. A biologia molecular representada pela Reação em Cadeia da Polimerase (PCR) 
trouxe a expectativa de ser uma ferramenta diagnóstica simples e sensível. No presente estudo, o 
desempenho de dois métodos de PCR usando alvos diferentes, PCR-P e PCR-LP, foi comparado com 
SSS no diagnóstico da hanseníase em um laboratório de referência. DNA de M. leprae foi extraído de 106 
amostras de linfa de 40 pacientes que apresentavam suspeita clínica de hanseníase. As amostras foram 
submetidas tanto a PCR como SSS. A amplificação do gene humano β-globina foi usada como controle 
de inibição da PCR. A especificidade de ambas as técnicas de PCR foi de 100% e a sensibilidade foi 
de 0,007 μg/mL e 0,015 μg/mL para a PCR-P e PCR-LP, respectivamente. Não se observou diferença 
estatística entre os resultados da PCR-LP e PCR-P, quando comparado com SSS (p > 0,05). Apesar 
de a PCR ainda não substituir o SSS no diagnóstico da hanseníase, esta técnica pode ser usada como 
ferramenta auxiliar eficiente para a detecção precoce da doença, especialmente em regiões endêmicas. 
Esta estratégia pode também ser útil nos casos em que os resultados de SSS forem negativos (ex. em 
pacientes paucibacilares) e em casos onde a biópsia da pele não pode ser realizada.
Unitermos: Hanseníase/diagnóstico clínico. Reação em Cadeia da Polimerase/uso em diagnóstico. 
Mycobacterium leprae.
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INTRODUCTION
Leprosy is a neglected tropical disease and still an 
important public health problem, especially in developing 
countries. A fast, sensitive, and specific diagnostic method 
is necessary for earlier detection to prevent disease 
progression, which can cause irreversible neural damage 
(Kurabachew Wondimu, Ryon, 1998).
Although leprosy is often diagnosed clinically, 
slit-skin smear (SSS) remains the laboratorial method of 
choice for leprosy confirmation and the classification of 
clinical forms of the disease. A negative SSS result does 
not necessarily exclude a diagnosis of leprosy. Patients 
with tuberculoid and indeterminate forms have a low 
number of bacilli that are present in the skin, referred to 
as paucibacillary leprosy (Banerjee et al., 2011).
Thus, a more sensitive diagnostic tool is urgently 
needed for the laboratorial diagnosis of leprosy, especially 
in such countries as Brazil. More than 90% of the number 
of registered cases in the Americas is found in Brazil 
(Banerjee et al., 2011; Araujo, 2003; WHO, 2008; PAHO, 
2007).
The advent  of  molecular  biology brought 
expectations for the diagnosis of infectious diseases, 
particularly uncultivable microorganisms in vitro, such 
as Mycobacterium leprae (Lavania et al., 2011; Millar, 
Xu, Moore, 1997). Polymerase chain reaction (PCR) has 
been used to detect M. leprae in lymph (Phetsuksiri, et 
al., 2006), blood (Almeida, 2004), nasal swab (Almeida, 
2004), tissue fragment (Phetsuksiri, et al., 2006; Martinez, 
2006), and urine (Caleffi et al., 2012, 2010; Parkash et al., 
2004) clinical samples.
Different PCR primers have been used to amplify the 
DNA of M. leprae from clinical samples (Kang, Kim, Lee, 
2003). The PCR targets that are used to detect M. leprae 
include genes that encode 36 kDa (known as proline-rich 
antigen [pra] (Parkash et al., 2004; Torres et al., 2003; 
Hartskeerl, De Wit, Klatser, 1989), 18 kDa (Chae et 
al., 2002), 85 kDa (Martinez et al., 2014), and 65 kDa 
(Plikaytis, Gelber, Shinnick, 1990) protein antigens, 16S 
rRNA (Phetsuksiri, et al., 2006), and repetitive sequences 
(Donoghue, Holton, Spigelman, 2001). Cox, Kempsell, 
Fairclough (1991) and Arnoldi et al. (1992) detected 8.3 
bacilli in skin biopsy samples using primers that amplified 
a specific sequence that was 172 bp from 16S rRNA. 
Donoghue, Holton, Spigelman (2001) also achieved the 
selective and specific detection of M. leprae in skin biopsy 
samples using a repetitive and specific region (RLEP) as 
the target.
In the present study, we compared two PCR 
protocols for the laboratorial diagnosis of leprosy and 




Patients from the Northwest of Parana State, which 
were under clinical diagnosis of leprosy, were selected 
for the study. The samples collection was carried out at 
the Laboratory for Teaching and Research in Clinical 
Analyses (LEPAC), reference center for the diagnosis 
of leprosy, at the University State of Maringa (UEM), 
Parana, Brazil, from November 2010 to November 2011. 
A total of 24.5% and 75.5 % of patients were classified by 
SSS as multibacillary and paucibacillary, respectively. No 
reactive disease cases were investigated during treatment 
time. The variables age, gender and family history of 
non-treated and under anti-leprosy therapy were analyzed.
Ethics Statement
The study was approved by the Ethics Committee 
of the State University of Maringa, Parana (protocol No. 
131/2006). The participation of children underage in the 
study occurred only after authorization and informed 
consent of parents or guardians. All participants approved 
the research protocol and signed the informed consent.
Biological sample
It was collected 106 lymph samples in different areas 
of the body from 40 patients: ear lobes (N = 29), elbows 
(N = 31), knee (N = 12), skin lesions (N = 33) and nodules 
(N = 1). The collected materials were stored in sterile 
microtubes containing 30 mL of sterile TE (10 mM Tris-
HCl, 1 mM EDTA, pH 8.0) and kept at -20 °C until use. 
DNA extraction in lymph samples
All lymph samples used for the SSS were submitted 
to DNA extraction for using in PCR. The M. leprae DNA 
was extracted using bacterial genomic DNA extraction 
kit (AxyPrep Minipreo Bacterial Genomic DNA Kit/
Axygen Biosciences) according to the manufacturer’s 
instructions. The extracted DNA samples were stored at 
-20 °C until use.
Specificity and sensitivity of the PCR
The PCR specificity was evaluated using DNA 
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extracted from M. leprae obtained from skin lesion of an 
armadillo experimentally infected and kindly supplied by 
the animal laboratory of the Institute Lauro de Souza Lima 
(São Paulo, Brazil). Reference strains M. tuberculosis 
H37Rv (ATCC 27.294), M. avium (ATCC 13950), M. 
kansasii (Lacen / Pr ATCC 0800), M. fortuitum (Lacen / 
PR), M. szulgai (Lacen / Pr ATCC 1300), M. smegmatis 
(Lacen/Pr) were also used for specificity test. The DNAs 
were extracted by phenol-chloroform method previously 
described by Cardoso et al. (2004).
The PCR sensitivity was determined using total M. 
leprae DNA (7.48 µg/mL), with dilutions ranging from 
1:2 (3.74 µg/mL) to 1:2048 (4 ng/mL).
PCR assay
S p e c i f i c  p r i m e r s  f o r  M .  l e p r a e ,  P 2 
(TAACGGAAACTCGGTAAAATCTT) and  P3 
(GCCGCACCTCATCAAAAAGCTT) for PCR-P 
and LP1 (TGCATGTCATGGCCTTGAGG) and LP2 
(CACCGACGGTACCAGCAGAA) for PCR-LP, which 
amplify DNA fragments of 172 bp of the gene encoding 
16S rRNA (Arnold et al., 1992) and 129 pb of repetitive 
and specific regions (RLEP) (Kang, Kim, Lee, 2003) were 
used, respectively.
T h e  p r i m e r s  P C O 4 
( C A A C T T C AT C C A C G T T C A C C )  a n d  G H 2 0 
(GAAGAGCCAAGGACAGGTAC) that amplify a 268 pb 
fragment of human β-globin gene were used as inhibitors 
sample control according to Rombaldi, Serafini, Mandelli 
(2008). 
The PCR assays were performed using 5 mL of 
template in 20 µL of the reaction mixture containing 
200 nM primers (Integrated DNA Technologies, 
USA) and PCR Master Mix (Promega Corporation, 
USA) according to manufacturer’s instructions. The 
amplifications were carried out in an ABI thermocycler 
(Mastercycler® gradient PCR, Germany), using 
the conditions described by Bang et al. (2009) and 
Donoghue, Holton, Spigelman (2001) for PCR-P and 
PCR-LP, respectively. 
PCR products were separated in 2% agarose 
gel electrophoresis in TBE buffer for 1 hour at 
100 volts and gel were stained with ethidium bromide 
(0.5 µg/mL). A 100 base pair DNA Ladder (Invitrogen life 
technologies, São Paulo, Brazil) was used as a molecular 
marker. Positive and negative controls were included in 
all amplification. In the positive controls, 5 µL of DNA 
extracted (0.15 µg/mL) from a skin lesion of armadillo 
was added to the PCR. For the negative controls, 5 µL of 
TE was added to the PCR.
Data analysis
Lymph samples that had a fragment of the 268 pb 
amplified in the PCR-Control (PC04-GH20 primers) 
were considered without PCR inhibitors, as suggested 
by Rombaldi, Serafini, Mandelli (2008). Samples were 
considered positive for M. leprae when a single PCR 
product of 172 bp and/or 129 pb was observed by PCR-P 
and PCR-LP, respectively. When the PCR-Control showed 
to be negative, it was repeated using DNA templates 
diluted to 1:2. Patients’ samples were considered negative 
when no amplification by specific primers was observed 
and amplification by PCR-Control was positive.
Data was analyzed using the McNemar test (software 
BioStat 5.0). The results were considered significant for 
p < 0.05.
RESULTS
A total of 40 patients participated in the study (17 
females [42.5%] and 23 males [57.5%]). The average age 
of the patients with leprosy was 53.15 years (range, 7-85 
years). Among the patients, 30 (75%) were in the diagnosis 
phase, and 10 (25%) had clinically confirmed leprosy and 
were undergoing treatment.
Both PCR-P and PCR-LP showed 100% specificity 
for M. leprae. No amplification was observed using DNA 
that was extracted from M. tuberculosis, M. avium, M. 
kansasii, M. fortuitum, M. szulgai, or M. smegmatis as the 
template. PCR-P and PCR-LP detected M. leprae DNA up 
to 1:512 (15 ng/mL) and 1:1024 (7 ng/mL), respectively.
The PCR-P, PCR-LP, and SSS results of the patient 
samples are described in Table I. All of the patients who 
were undergoing treatment had positive results in both 
PCR assays and the SSS assay. One lymph sample (1.43%) 
of a patient who was in the diagnosis phase had a negative 
SSS result and positive PCR-LP result.
No significant difference was found between the 
SSS results and PCR-P (p = 0.134) or PCR-LP (p = 1.000) 
results. PCR-LP and PCR-P had comparable performance 
in detecting M. leprae DNA in lymph samples (p = 0.074; 
Table I).
The PCR-Control technique presented initial 
inhibition in 19 of 106 (17.92%) of the lymph samples. 
After dilution of the DNA template (1:2), inhibition 
persisted in 15 of 106 (14.15%) of the analyzed samples.
The lymph that was obtained from ear lobe and skin 
lesions showed greater positivity in the PCR-P and PCR-
LP assays in 6 of 7 samples (86%) and 7 of 7 samples 
(100%), respectively (data not shown).
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DISCUSSION
The transmission of leprosy still occurs despite the 
availability of effective treatment. It is a disease with a 
long incubation time, and the symptoms are difficult to 
recognize, mainly in the early stage of the disease. Self-
healing occurs in a large number of infected individuals, 
and many patients with early signs are unaware that they 
are suffering from leprosy, thus often delaying clinical 
diagnosis (Banerjee et al., 2010). Clinical diagnosis is 
possible only when the patient is symptomatic, exhibiting 
skin lesions or presenting the clinical criteria of cardinal 
signs of leprosy (Martinez et al., 2006). Polymerase 
chain reaction may be an important tool for helping 
diagnose leprosy in cases in which clinical findings and 
SSS are inconclusive, such as with pure neural leprosy, 
paucibacillary cases, and atypical clinical presentation 
(Martinez et al., 2014).
An early laboratory diagnosis of leprosy still presents 
difficulties. The SSS technique shows low sensitivity in 
detecting acid-fast bacilli, and a trained professional must 
perform the smear readings. Because a negative SSS result 
does not necessarily exclude a diagnosis of leprosy, an 
assay with higher sensitivity is needed for the detection 
of M. leprae.
More male than female patients participated in the 
present study. There was a predominance of economically 
active population, with an average age of 53.15 years, 
which is consistent with the existing literature (Gomes, 
Pontes, Gonçalves, 2005). 
The specificity of PCR-P and PCR-LP in the 
detection of M. leprae was comparable to the specificity 
reported by Bang et al. (2009) and Donoghue, Holton, 
Spigelman (2001). With regard to sensitivity, PCR-LP 
had a higher ability to detect DNA of M. leprae in lymph 
samples. According to Donoghue, Holton, Spigelman 
(2001), the higher sensitivity of PCR-LP may be 
associated with amplification of a 28-repeat fragment in 
the genome of M. leprae.
Higher positivity in detecting DNA of M. leprae 
was found in lymph samples that were collected from 
ear lobe and skin lesions, with comparable performance 
between PCR-P and PCR-LP. These data reinforce the 
need to collect lymph samples from cold areas of the 
body (e.g., the ears, elbows, knees) to diagnose leprosy, 
as recommended by the Brazilian Ministry of Health 
(Brasil, 2014).
No significant difference was found between the 
PCR-LP or PCR-P results and SSS results (p > 0.05). 
Although no significant results were observed, the use 
of PCR as an additional diagnosis tool was extremely 
beneficial for one patient. The positive PCR results 
allowed an early diagnosis of leprosy, prompting the 
initiation of treatment. An analysis with a larger number 
of leprosy patients may reveal higher PCR sensitivity 
compared with SSS, as demonstrated by other studies 
(Bang et al., 2009; Martelli, Stefani, Penna 2002).
The use of control primers (PC04-GH20) that are 
specific for human DNA (human b-globin) showed good 
performance in determining the quality of the sample that 
was subjected to specific PCR. A significant percentage 
of PCR inhibition was observed in the samples (19 of 106 
[17.92%]). Some substances, such as nitrate, urea, proteins, 
blood, and even high levels of human genomic DNA, have 
been shown to prevent amplification in the PCR assay 
(Martinez et al., 2006; Toye, Woods, Bobrowska, 1998). In 
the present study, all of the samples that showed inhibition 
in the PCR-Control assay were retested with 1:2 diluted 
extracted samples. This procedure showed improvement 
in detecting M. leprae in four additional lymph samples. 
However, 15 of 106 (14.15%) lymph samples continued to 
show PCR inhibition. Importantly, dilution of the extracted 
sample needs to be considered because diluted inhibitors 
will consequently dilute M. leprae DNA and can make the 
detection of specific DNA more difficult in some cases.
Generally, both PCR assays had sufficient sensitivity 
to detect some M. leprae bacilli which could not otherwise 
be detected by SSS. Detecting M. leprae is crucial for 
diagnosing some cases of leprosy and correctly classifying 
patients for treatment, and PCR is expected to make a 
precise diagnosis (Sugita, 2001). Concern arises regarding 
the classification of patients into paucibacillary or 
multibacillary leprosy to guide therapy. Currently, negative 
SSS results indicate paucibacillary leprosy, and positive 




+ (%) - (%) + (%) - (%)
PCR-LP 22 (24.17) 69 (75.83) 21 (23.08) 70 (76.92) 1.000
PCR-P 17 (18.68) 74 (81.32) 0.134
p = 0.074, McNemar test, PCR- LP vs PCR- P. **The samples with inhibitors, in the PCR assay, were excluded (15/106; 14.15%).
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results indicate multibacillary leprosy. This classification 
should be reconsidered if PCR is implemented in routine 
laboratory practice.
Importantly, nucleic acids that are detected by PCR 
in lymph samples do not necessarily indicate the presence 
of viable M. leprae (Speers, 2006). A positive result by 
PCR, as by SSS, in patients’ samples can spend variable 
time to become negative after the start of antimicrobial 
therapy. Thus, the use of PCR to detect M. leprae is a 
promising tool during the stage of leprosy diagnosis.
Notably, PCR may be an important adjunct tool 
in the diagnosis of leprosy, but it still cannot replace 
conventional laboratory methods. In developed countries, 
this technique has been used as an aid in the diagnosis of 
difficult cases of leprosy (Martelli, Stefani, Penna, 2002). 
Over the years, this method has become more accessible to 
various laboratories and can be especially useful in cases 
in which SSS results are negative and in cases in which 
skin biopsy cannot be performed, such as with atypical 
locations of lesions (Katoch, Lavania, Chauhan, 2010).
The present study compared SSS and PCR 
techniques using lymph samples, which is a conventional 
biological material that is routinely collected for the 
laboratory diagnosis of leprosy. One limitation of the 
present study, however, was the relatively low number of 
clinical samples and primers tested. Nonetheless, PCR-LP 
showed good sensitivity concomitantly with the SSS assay. 
Further studies are necessary to standardize and optimize 
PCR techniques in the laboratory diagnosis of leprosy.
CONCLUSION
The present study found that PCR can be beneficial 
as an efficient auxiliary tool, especially in endemic regions, 
for leprosy diagnosis in conjunction with SSS, although it 
cannot replace the SSS assay and still remains inaccessible 
to many laboratories with few financial resources. 
Polymerase chain reaction can also be useful for patients 
with negative SSS findings and for patients in whom skin 
biopsy cannot be performed.
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